STOCKS TELEGRAPH

Tag: AGRX

  • Agile Therapeutics (AGRX): Navigating Market Volatility with Strategic Moves

    Agile Therapeutics (AGRX), a prominent player in women’s healthcare, is garnering attention for its innovative contraceptive solutions. Their flagship product, Twirla®, offers women a convenient alternative to daily birth control pills through the revolutionary Skinfusion® transdermal patch technology.

    Market Turbulence

    Yesterday, Agile Therapeutics Inc. (NASDAQ: AGRX) experienced a sharp decline of over 5.5% in its stock value, causing ripples of concern among investors. However, in a surprising turn of events during premarket trading today, the company witnessed an astounding surge of 112%, doubling its stock price to $2.10. This unexpected reversal has left market observers perplexed, as there is no apparent catalyst to justify such a dramatic upswing.

    Compliance Extension and Performance Update:

    Delving deeper, it was revealed that this surge could be linked to news from at least a week ago.

    Agile Therapeutics recently announced that it has been granted an extension by the Nasdaq Hearings Panel to regain compliance with the stockholders’ equity requirement for continued listing. This extension, providing until March 25, 2024, to meet Nasdaq’s stringent criteria, has injected renewed optimism into the market.

    Furthermore, Agile Therapeutics shared its preliminary performance outlook for the full year 2023. Expecting robust growth, the company projects net revenue to range from $20 to $21 million, marking an impressive 84% to 93% increase compared to the previous year.

    Additionally, Agile Therapeutics anticipates a significant reduction in operating expenses for 2023, estimating them to range from $30 to $31.5 million, signaling a noteworthy decrease of 44% to 47%.

    Conclusion

    These promising developments underscore Agile Therapeutics’ commitment to delivering value to its shareholders while advancing its mission to provide women with accessible and effective contraceptive options.

    As the company navigates regulatory requirements and pursues growth strategies, investors remain cautiously optimistic about its future trajectory amidst market volatility.

  • Agile Therapeutics Inc. (AGRX) stock Continues its Rally on Rebound Energy

    The long-beaten down transdermal patch developer, Agile Therapeutics Inc. (AGRX) made its comeback on Tuesday. Having bounced back on April 12, the stock rallied in both the regular and after-hours sessions with gains of 47.18% and 27.74% respectively. Thus, after spiking up to $0.1878 in regular trading, AGRX reached $0.2399 in the after hours.

    Source: iStock

    There is no official news or SEC filing from the company behind the comeback.

    AGRX Stock Analysis

    AGRX stock has been plunging down since the company posted missed earnings on March 30, 2022. While the stock was already in a downtrend, the latest news of its sale of tax benefits on April 11 did more harm than good to the stock. Thus, continuing the downtrend, the stock plunged down to a near low on April 11 and closed the session slightly above it. Having a good deal of rebound energy stored over time, the stock finally made a comeback on April 12. Given that there is no other news from the company, the rebound seems to be caused by external factors.

    Market Situation

    Among other external factors like social media discussions and stock sentiment etc., the market situation could also be a cause of the rebound. With the prevailing uncertainty in the market due to multiple factors, investors are trying to make safe bets. Currently, healthcare stocks are one of the safe havens for investors as they are less likely to be impacted by crises and conflicts among other instabilities. Therefore, investors are gladly buying the current dip in AGRX stock as the wider market remains under the cloud of high volatility.

    Sale of Tax Benefit

    On Tuesday, the company announced receiving net proceeds of $4.7 million from the sale of tax benefits through the New Jersey economic development program. The company participated in the Net Operating Loss (NOL) program of the New Jersey Economic Development Authority (NJEDA) under the New Jersey Economic Recovery Act of 2020. The program allows NJ-based tech and bio-tech companies to cash their NOLs through sales to unrelated profitable corporations. Thus, tax losses and credits are turned into cash proceeds for funding growth and operations.

     AGRX’s 2022 Plans

    By 2022 the company has focused its business plan on boosting demand for its transdermal contraceptive Twirla. As per the plans, AGRX has partnered with Afaxys for a co-promotion program and expects to launch a DTC commercial on connected TV this month.

    Additionally, the company will also be holding a Special Meeting of Stockholders this month for approval of a reverse stock split in order to regain compliance with Nasdaq.

  • Update on Participation in Investor Events: Agile Therapeutics, Inc. (AGRX) Stock Rebounds After Hours.

    Agile Therapeutics, Inc. (AGRX) is focused on the fulfillment of women’s unmet health needs. It offers women contraceptive options and the preliminary product of the company is Twirla transdermal system.

    AGRX stock price in the regular trading on March 11, 2022, with a decrease of 6.58% was $0.26. Its price rebounded by 7.31% at the last check of the aftermarket session.

    AGRX: Events and Happenings

    On March 11, 2022, AGRX reported its Executive management to present at the following investor conferences.

    • Virtual Oppenheimer’s 32ndAnnual Healthcare Conference was held on March 17, and
    • Virtual Maxim Group and M-Vest 2022 Growth Conference held on March 28, 2022.

    On March 07, 2022, AGRX announced to issue its fourth-quarter 2021 financials on March 30, 2022. On January 12, 2022, AGRX acknowledged the issuance of guidelines by the tri-agencies, Department of Labor, Health and Human Services, and Treasury to aid in women’s accessibility to FDA-approved contraceptives. On January 10, 2022, AGRX informed the press about its collaboration with Afaxys Pharma, for the promotion of the Twirla transdermal system.

    AGRX: Key Financials

    On November 2, 2021, AGRX released its consolidated third-quarter 2021 financial report for the period ended September 30, 2021. Some important aspects are mentioned below.

    Revenue

    Net revenue delivered by the company in Q3 2021 was $1.3 million compared to no revenue in the same period of 2020. The company reported a 100% surge in its YoY net revenue. Also, it missed the revenue target by $175.2 thousand.

    EPS

    Net loss basic and diluted per share for the company during Q3 2021 was $16.8 million or $0.18 against $15.5 million or $0.18 in the same quarter of 2020. The company topped the EPS estimates by $0.01 and its net loss inclined YoY.

    Conclusion

    AGRX stock is down-performing as it hit 50% year-to-date as the pandemic-related economic restrictions are going to ease internationally. The company announced the upcoming presentation of its Executive management at the virtual investor’s conferences, resultantly its stock swelled. Also, the company is estimating $1.51 million revenue for Q4 2021 against -$0.15 EPS.

  • Agile Therapeutics Inc. (AGRX) Stock Exhibits Minor Volatility Following Promising Q2 2021 Financial Reports

    Agile Therapeutics Inc. (AGRX) stock prices were down 3.45% as of market closing on July 26th, 2021, bringing the price per share down to USD$1.12 at the end of the trading day. Subsequent premarket fluctuations saw the stock rise by 4.46%, bringing it up to USD$1.17.

    AGRX Stock Prescriptions Improved

    The second quarter of 2021 saw AGRX stock report total prescriptions coming in at 5,027, up a massive 171% from the numbers reported for the prior quarter. New prescriptions were up 103% over the quarter, reported at 2,857. These increases were driven by increases in the number of prescribers and growing refill rates. As of June 30th, 2021, the company reported more than 2,087 healthcare providers, while 2,033 prescriptions were dispensed as refills. Up 355% from the prior quarter. AGRX also reported an increase in the total number of prescriptions per prescriber.

    AGRX Stock’s Market Reach

    AGRX stock has continued expanding the market footprint of Twirla, with it being available to Medicaid patients across roughly 75%, either through traditional and/or managed Medicaid. This development sees Twirla cover roughly half of the total Medicaid transdermal TRx market with no restrictions. Based on claims, Twirla reports having access to roughly 55% of the commercial and government CHC market.

    Cost of Product Revenue

    Cost of product revenues for the quarter ended June 30th, 2021 was reported at USD$1.1 million and included direct and indirect expenses. These costs supported AGRX stock’s manufacturing and distribution efforts, including, but not limited to, personnel costs and roughly USD$500,000 of non-cash depreciation expense. These relatively fixed costs are expected to stay roughly the same as sales increase with expected volume increases.

    Additional Financials

    AGRX stock was selling units from validation batches until May 2021, with no associated product cost on account of the cost having been previously expensed already. Roughly 76% of the units sold over the second quarter of 2021 had an associated product cost, as will all future sales of the product. As of June 30th, 2021, the company reported USD$31.1 million in cash, cash equivalents, and marketable securities. This is compared to the USD$54.5 million reported as of December 31st, 2020.

    Future Outlook for AGRX

    With the company’s flagship Twirla gaining traction and snowballing in sales, AGRX stock is poised to capitalize on the increasing momentum. The company is keen to continue its trajectory of success as it effectively allocated its resources to stay lean. Current and potential investors are hopeful that management will be able to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • 15 Top Performing Stocks In Healthcare Industry

    15 Top Performing Stocks In Healthcare Industry

    The health care industry is considered to be the opportunity-rich industry. The demand in this industry is continuously increasing. Emerging technologies also play a very important role in the health care industry. Complex health and technology ecosystems and increasing consumer expectations are the major challenges which the health care industry is facing. Customers’ main priority is affordable and efficient drugs.

    If we look at the Drug manufacturers and specialty generic industry, this industry has seen a huge transformation over the last two decades. This industry is always striving to change fast enough to keep up with regulatory and patients needs. Currently, the healthcare industry has faced the major challenge of the COVID-19 pandemic. It is important to focus on what is happening in the market to increase industry growth.

    Here are the 15 leading companies in the Drug Manufacturers and specialty and generic industry:

    Zomedica Pharmaceuticals Corp. (AMEX: ZOM)

    Zomedica Pharmaceuticals Corp. (AMEX: ZOM) shares were trading up 42.86% at $0.10 at the time of writing on Monday. Zomedica Pharmaceuticals Corp. (AMEX: ZOM) share price went from a low point around $0.07 to briefly over $0.50 in past 52 weeks, though shares have since pulled back to $0.10. ZOM market cap has remained high, hitting $79.71M at the time of writing.

    Zomedica Pharmaceuticals Corp. has earlier revealed its proxy solicitor, Alliance Advisors, mailed the letter to selected shareholders in advance of its Annual and Special Virtual-Only Meeting of Shareholders. The virtual meeting is scheduled to hold on September 25, 2020.

    AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX)

    AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) last closed at $1.81, in a 52-week range of $0.70 to $2.68. AcelRx Pharmaceuticals Inc. (ACRX) announced today that the U.S. Army has granted AcelRx with an initial contract of up to approximately $3.6 million for the purchase of DSUVIA to support a study to aid the development of clinical practice guidelines. This company’s market capitalization has remained high, hitting $142.61 million at the time of writing.

    PPD Inc. (NASDAQ: PPD)

    PPD Inc. (NASDAQ: PPD) stock soar by 0.92% to $34.16. The most recent rating by KeyBanc Capital Markets, on June 04, 2020, is at an Overweight. PPD Inc. (PPD) has earlier revealed that it has received the honor of employer of choice around the world. PPD was recognized as a top 50 desirable employer in Bulgaria, according to the second annual Employer of Choice Survey organized by the employer brand and business consulting agency To The Top. This company market capitalization has remained high, hitting $11.61 billion at the time of writing.

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)

    Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) last closed at $0.80, in a 52-week range of $0.27 to $1.51. Analysts have a consensus price target of $1.25. Adamis Pharmaceuticals Corporation (ADMP) has earlier revealed the pricing of its previously announced underwritten public offering of 16,129,032 shares of its common stock at a public offering price of $0.62 per share, resulting in gross proceeds of approximately $10,000,000.

    Rockwell Medical Inc. (NASDAQ: RMTI)

    Rockwell Medical Inc. (NASDAQ: RMTI) last closed at $1.76, in a 52-week range of $1.10 to $3.85. Rockwell Medical Inc. (RMTI) has earlier named Russell L. Skibsted, M.B.A., as Executive Vice President, Chief Financial Officer  and Chief Business Officer (CBO), effective from September 15, 2020. This company market capitalization has remained high, hitting $96.44 million at the time of writing.

    TherapeuticsMD Inc. (NASDAQ: TXMD)

    TherapeuticsMD Inc. (NASDAQ: TXMD) stock soars 2.75% to $1.44. The most recent rating by Jefferies, on August 07, 2020, is at an Underperform. TherapeuticsMD Inc. (TXMD) Knight Therapeutics Inc. and TherapeuticsMD, Inc. revealed that they received the approval of BIJUVA® (estradiol and progesterone) capsules by Health Canada. This company has a market capitalization of $368.06 million at the time of writing.

    Zoetis Inc. (NYSE: ZTS)

    Zoetis Inc. (NYSE: ZTS) rose 0.06% after gaining more than $0.01 on Tuesday. Zoetis Inc. (ZTS) has been recognized by Working Mother magazine for its career advancement opportunities, female representation and work-life programs. in the past 52-weeks of trading, Zoetis stock has fluctuated between the low of $90.14 and a high of $165.82. ZTS has moved up 78.59% from its 52-weeks low and moved down -2.92% from its 52-weeks high.  ZTS market cap has remained high, hitting $76.29 billion at the time of writing.

    DURECT Corporation (NASDAQ: DRRX)

    DURECT Corporation (NASDAQ: DRRX) stock drop by -5.41% to $1.75. The most recent rating by Oppenheimer, on July 31, 2020, is at an Outperform. DURECT Corporation (DRRX) has revealed the study design for the Phase 2b AHFIRM clinical trial of DUR-928 in severe alcoholic hepatitis (AH) patients. DURECT Corporation market cap has remained high, hitting $333.92 million at the time of writing.

    Elanco Animal Health Incorporated (NYSE: ELAN)

    Elanco Animal Health Incorporated (NYSE: ELAN) shares headed rising, higher as much as 0.56%. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Overweight. In the past 52-weeks of trading, this company stock has fluctuated between the low of $15.17 and a high of 32.66. Elanco Animal Health Incorporated (ELAN) has moved up 76.01% from its 52-weeks low and moved down -18.25% from its 52-weeks high.

    Guardion Health Sciences Inc. (NASDAQ: GHSI)

    Guardion Health Sciences Inc. (NASDAQ: GHSI) rose 1.22% on Monday. Guardion Health Sciences Inc. (GHSI) share price went from a low point around $0.17 to briefly over $0.95 in the past 52 weeks, though shares have since pulled back to $0.25. Guardion Health Sciences Inc.’s market cap has remained high, hitting $22.26 million at the time of writing.

    Agile Therapeutics Inc. (NASDAQ: AGRX)

    Agile Therapeutics Inc. (NASDAQ: AGRX) shares headed falling, lower as much as -6.89%. The most recent rating by Janney, on April 12, 2019, is at a Buy. In the past 52-weeks of trading, Agile Therapeutics Inc. stock has fluctuated between the low of $0.35 and a high of $4.77. Agile Therapeutics Inc. has moved up 807.14% from its 52-weeks low and moved down -33.37% from its 52-weeks high.

    Momenta Pharmaceuticals Inc. (NASDAQ: MNTA)

    Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) stock drops 0.02% after losing -0.01 on Tuesday. Momenta Pharmaceuticals Inc. (MNTA) share price went from a low point around $12.21 to briefly over $52.45 in the past 52 weeks, though shares have since pulled back to $52.36. Momenta Pharmaceuticals Inc.’s market cap has remained high, hitting $6.24 billion at the time of writing.

    Catalent Inc. (NYSE: CTLT)

    Catalent Inc. (NYSE: CTLT) stock drop 0.86% to $84.81. The most recent rating by Argus, on June 25, 2020, is at a Buy. In the past 52-weeks of trading, Catalent Inc. (CTLT) stock has fluctuated between the low of $31.04 and a high of $95.70. Catalent Inc. has moved up 173.23% from its 52-weeks low and moved down -11.38% from its 52-weeks high.  Catalent Inc. market cap has remained high, hitting $13.94 billion at the time of writing.

    Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD)

    Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) shares headed falling, lower as much as 2.22%. The most recent rating by Northland Capital, on June 17, 2020, is at an Outperform. Ironwood Pharmaceuticals Inc. (IRWD) share price went from a low point around $7.91 to briefly over $14.10 in the past 52 weeks, though shares have since pulled back to $9.48. Ironwood Pharmaceuticals Inc.’s market cap has remained high, hitting $1.54 billion at the time of writing.

    Athenex Inc. (NASDAQ: ATNX)

    Athenex Inc. (NASDAQ: ATNX) last closed at $12.80, in a 52-week range of $5.63 to $18.35. Athenex Inc. (ATNX) has moved up 127.35% from its 52-weeks low and moved down -30.25% from its 52-weeks high.  Athenex Inc. market cap has remained high, hitting $1.14 billion at the time of writing.

  • Here’s 15 Trending Stocks In Healthcare Industry To Watch

    Here’s 15 Trending Stocks In Healthcare Industry To Watch

    The global drug manufacturers specialty & generic industry continues to grow with the increase in the demand for medication. Efficient and inexpensive drugs are the main priority of customers. Drug manufacturing is more progressive with the advent of new technologies than other areas of the pharmaceutical industry. Companies are busy in acquisitions, collaborations to increase the specialty generic capacities.

    The development of cost-effective drugs and specialty generics is a complex process.  The drug generic market has seen a huge transformation over the last few decades. Its main competitive edge is the lower prices than branded drugs. The generic industry has experienced various changes as the coronavirus pandemic takes over the world. The purchase behaviors of customers also change in 2020.

    There are various companies which are fulfilling the needs of customers in the generic industry. Here are the top 15 best players in Drug manufacturers Specialty and Generic Industry:

    Zomedica Pharmaceuticals Corp. (AMEX: ZOM)

    Zomedica Pharmaceuticals Corp. (AMEX: ZOM) shares were trading down -2.18% at $0.11 at the time of writing on Friday. Zomedica Pharmaceuticals Corp. (AMEX: ZOM) share price went from a low point around $0.10 to briefly over $0.50 in past 52 weeks, though shares have since pulled back to $0.11.

    Zomedica Pharmaceuticals Corp. (ZOM) is scheduled to present at H.C. Wainwright Virtual Global Investment Conference on September 14, 2020. Zomedica has earlier partnered with Qorvo Biotechnologies to develop three new assays Cobalamin, Canine Pancreatic Lipase, and Folate to target the diagnosis of canine gastrointestinal issues. ZOM market cap has remained high, hitting $62.09M at the time of writing.

    Teva Pharmaceutical Industries Limited (NYSE: TEVA)

    Teva Pharmaceutical Industries Limited (NYSE: TEVA) last closed at $8.79, in a 52-week range of $6.25 to $13.76. Analysts have a consensus price target of $12.19. Teva Pharmaceutical Industries Limited (TEVA) affiliate Teva Neuroscience, Inc. earlier disclosed that new study data on AUSTEDO will be presented at the International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2020) and during the Psych Congress 2020 Virtual Experience. Teva market cap has remained high, hitting $9.79 billion at the time of writing.

    Mylan N.V. (NASDAQ: MYL)

    Mylan N.V. (NASDAQ:; MYL) stock soar by 1.79% to $15.33. The most recent rating by SVB Leerink, on January 27, 2020, is at an Mkt perform. Mylan N.V. (MYL) has earlier bought Aspen Pharmacare Holdings Limited’s thrombosis business in Europe for €641.9 million. Mylan will pay the upfront payment of €263.2 million to Aspen. After generating cash from existing operations it will pay the €378.7 million on June 25, 2021. It has a market capitalization of $7.79 billion at the time of writing.

    Aurora Cannabis Inc. (NYSE: ACB)

    Aurora Cannabis Inc. (NYSE: ACB) last closed at $6.98, in a 52-week range of $5.30 to $78.00. Aurora Cannabis Inc. (ACB) has earlier appointed Miguel Martin its chief executive officer and also disclosed that it would book up to C$1.8 billion ($1.37 billion) in restructuring charges. It has a total market capitalization of $785.74 million at the time of writing.

    Bausch Health Companies Inc. (NYSE: BHC)

    Bausch Health Companies Inc. (NYSE: BHC) fall -1.60% after losing more than -$0.25 on Friday. Bausch Health Companies Inc. (BHC) has earlier shared its Inaugural Activity Report which showed the efforts of the Foundation from late 2017 through June 30, 2020.  Bausch Health Companies Inc. striving to improve the lives of patients globally. It has a total market cap of $5.58 billion at the time of writing.

    Endo International plc (NASDAQ: ENDP)

    Endo International plc (NASDAQ: ENDP) last closed at $2.80, in a 52-week range of $2.08 to $7.10. Endo International plc (ENDP) has earlier participated in the Citi 15th Annual BioPharma Virtual Conference being held on September 8-10, 2020. Endo International plc market cap has remained high, hitting $629.69 million at the time of writing.

    Sundial Growers Inc. (NASDAQ: SNDL)

    Sundial Growers Inc. (NASDAQ: SNDL) Shares headed falling, lower as much as -0.50%. The most recent rating by CIBC, on August 17, 2020, is at a Neutral. Sundial Growers Inc. (NASDAQ: SNDL) is scheduled to participate in
    Alliance Global Partners’ Consumer Cannabis Conference. Zachary George, Chief Executive Officer of Sundial, will take part in one-on-one sessions on September 29, 2020.

    Cronos Group Inc. (NASDAQ: CRON)

    Cronos Group Inc. (NASDAQ: CRON) fall -1.51% after losing more than -$0.08 on Friday. Cronos Group Inc. (NASDAQ: CRON) announced that its Board of Directors has named Kurt Schmidt President and Chief Executive Officer of the Company, effective September 9, 2020.  CRON also disclosed that Mike Gorenstein has been chosen as the Executive Chairman. Mike has worked as Chairman, President, and Chief Executive Officer of Cronos Group since 2016.

    Elanco Animal Health Incorporated (NYSE: ELAN)

    Elanco Animal Health Incorporated (NYSE: ELAN) last closed at $27.08, in a 52-week range of $15.17 to $32.66. Analysts have a consensus price target of $26.43. Elanco Animal Health Incorporated (NYSE: ELAN) is scheduled to participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Tuesday, September 15, 2020.  Elanco Animal Health Incorporated market cap remained high, hitting $10.86 billion at the time of writing.

    Agile Therapeutics Inc. (NASDAQ: AGRX)

    Agile Therapeutics Inc. (NASDAQ: AGRX) stock soar by 2.54% to $3.63. The most recent rating by Janney, on April 12, 2019, is at a Buy. Agile Therapeutics Inc. (AGRX) is scheduled to host a virtual investor/Analyst day on Monday, September 21, 2020. It has also introduced I’m So Done, an education and empowerment platform that encourages women to think about their current contraceptive method and decision-making journey.

    Mallinckrodt plc (NYSE: MNK)

    Mallinckrodt plc (NYSE: MNK) Shares headed falling, lower as much as -7.69%. The most recent rating by JP Morgan, on May 19, 2020, is at an Underweight. Mallinckrodt plc (MNK) share price went from a low point around $1.00 to briefly over $6.42 in the past 52 weeks, though shares have since pulled back to $1.20. Mallinckrodt plc market cap has remained high, hitting $110.00 million at the time of writing.

    HEXO Corp. (NYSE: HEXO)

    HEXO Corp. (NYSE: HEXO) fall -2.82% after losing more than -$0.02 on Friday. HEXO Corp. (HEXO) share price went from a low point around $0.35 to briefly over $4.62 in the past 52 weeks, though shares have since pulled back to $0.62. HEXO Corp. market cap has remained high, hitting $331.70 million at the time of writing

    Tilray Inc. (NASDAQ: TLRY)

    Tilray Inc. (NASDAQ: TLRY) stock drop by -5.68% to $5.31. The most recent rating by The Benchmark Company, on May 12, 2020, is at a Buy. Tilray Inc. (TLRY) stock fluctuated between the 52-weeks low range of $2.43 and a high range of $32.77. It has moved up 118.52% from its 52-weeks low and moved down -83.80% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 1.80. Its market capitalization is $716.00 million.

    Momenta Pharmaceuticals Inc. (NASDAQ: MNTA)

    Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) shares headed falling, lower as much as -0.12%. The most recent rating by Cowen, on August 03, 2020, is at an Outperform. Momenta Pharmaceuticals Inc. (MNTA)  share price went from a low point around $12.21 to briefly over $52.33 in the past 52 weeks, though shares have since pulled back to $52.08. Momenta Pharmaceuticals Inc. market cap has remained high, hitting $6.20 Billion at the time of writing

    Aphria Inc. (NASDAQ: APHA)

    Aphria Inc. (NASDAQ: APHA) stock drop by -2.81% to $4.50. The most recent rating by CIBC, on August 17, 2020, is at a Sector outperform. Aphria Inc. (APHA) stock fluctuated between the 52-weeks low range of $1.95 and a high range of $7.04. It has moved up 130.77% from its 52-weeks low and moved down -36.08% from its 52-weeks high. Its market capitalization is $1.20 Billion.